This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Top Stocks Likely to Beat Earnings Estimates This Season
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Repligen (RGEN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RGEN) Outperforming Other Medical Stocks This Year?
EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. RGEN: Which Stock Is the Better Value Option?
LGND or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. RGEN: Which Stock Is the Better Value Option?
LGND or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. RGEN: Which Stock Is the Better Value Option?
Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks
by Aniruddha Ganguly
Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.
Repligen (RGEN) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QGEN vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
by Zacks Equity Research
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
Profit From 5 Stocks Likely to Beat on Earnings
by Sanghamitra Saha
Bet on five stocks that are likely to outdo earnings estimates.
Why Repligen (RGEN) Might be Well Poised for a Surge
by Zacks Equity Research
Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 45.46% and 5.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXEL or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. RGEN: Which Stock Is the Better Value Option?
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.
Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
Should Growth Investors Buy this Cancer Screening Biotech Stock?
by Benjamin Rains
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Intercept (ICPT) Concludes Enrollment in Study on NASH Drug
by Zacks Equity Research
Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
by Zacks Equity Research
ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.
Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RGEN) Outperforming Other Medical Stocks This Year?
3 Reasons Growth Investors Will Love Repligen (RGEN)
by Zacks Equity Research
Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.